Target intelligence / Profile preview

Influenza virus polymerase acidic protein (PA) cap-dependent endonuclease domain (PA-CEN)

Target
PA-CEN
Molecular classification
Enzyme, Endonuclease, Viral RNA-dependent RNA polymerase subunit
01

Overview

The Influenza virus polymerase acidic protein (PA) cap-dependent endonuclease domain is a critical component of the heterotrimeric viral RNA-dependent RNA polymerase (RdRp) complex, which also includes the PB1 and PB2 subunits (UniProt: P03433). This specific N-terminal domain of the PA protein is responsible for the "cap-snatching" mechanism, a process where the virus cleaves the 5' methylated cap from host cellular pre-mRNAs to use as primers for its own viral mRNA synthesis (PubMed: PMC6466463). Because this endonuclease activity is essential for viral replication and is highly conserved across various influenza strains, it serves as a potent therapeutic target. Drugs like baloxavir marboxil specifically bind to the active site of this domain, which contains two divalent metal ions, thereby inhibiting the cleavage of host RNA (PubChem: CID 124081523). By blocking this early step in the viral life cycle, these inhibitors effectively halt the production of viral proteins and the assembly of new virions. Resistance to such treatments can emerge through specific amino acid substitutions in the PA domain, most notably the I38T mutation, which reduces the binding affinity of the inhibitor (PubMed: PMC6663284).

Other names
PA endonucleaseInfluenza PA-N domainCap-dependent endonucleasePolymerase acidic protein N-terminal domain
02

Mechanism of action

Inhibition of the cap-dependent endonuclease activity within the PA subunit of the viral RNA polymerase complex, which prevents the cleavage of host pre-mRNAs and the subsequent priming of viral mRNA synthesis (cap-snatching).

03

Biological functions

Viral mRNA synthesisCap-snatchingRNA cleavageViral replication
04

Disease associations

Influenza A infectionInfluenza B infection
05

Safety considerations

Emergence of drug-resistant variants (e.g., I38T substitution)Gastrointestinal side effectsHypersensitivity reactions
06

Interacting drugs

Baloxavir marboxil

1 more in the full profile.

07

Biomarkers

PA I38T mutationPA I38M mutationPA I38F mutationViral RNA load

Beyond the preview

Go deeper on Influenza virus polymerase acidic protein (PA) cap-dependent endonuclease domain (PA-CEN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza virus polymerase acidic protein (PA) cap-dependent endonuclease domain (PA-CEN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call